SUBSCRIBE
SUBSCRIBE

Immunic Therapeutics

NEWS
Multiple sclerosis damaged myelin or MS autoimmune disease with healthy nerve with exposed fibre with scarrred cell sheath loss as a 3D illustration.
Multiple sclerosis
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management
While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.
October 6, 2025
 · 
5 min read
 · 
Ben Hargreaves
IN THE PRESS
Press Releases
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 19, 2026
 · 
7 min read
Press Releases
Immunic to Participate in Investor and Medical Conferences in May 2026
April 30, 2026
 · 
5 min read
Press Releases
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 28, 2026
 · 
10 min read
Press Releases
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
April 23, 2026
 · 
7 min read
Press Releases
Immunic to Participate in Scientific and Medical Conferences in April 2026
April 9, 2026
 · 
5 min read
Press Releases
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 1, 2026
 · 
5 min read
Press Releases
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
March 31, 2026
 · 
7 min read
Press Releases
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 10, 2026
 · 
9 min read
Press Releases
Immunic to Participate in Investor Conferences in March 2026
March 3, 2026
 · 
5 min read
Press Releases
Immunic Announces Closing of Oversubscribed Private Placement Financing
February 18, 2026
 · 
7 min read
Load More
JOBS